Therapy Areas: Oncology
Takeda to Acquire Adaptate Biotherapeutics to Develop Novel Gamma Delta T Cell Engager Therapies Targeting Solid Tumors
11 January 2022 - - Japan-based Takeda Pharmaceutical Company Ltd. (TSX: 4502) (NYSE: TAK) has exercised its option to acquire Adaptate Biotherapeutics, a UK company focused on developing antibody-based therapeutics for the modulation of variable delta 1 gamma delta T cells, the company said.

Through the acquisition, Takeda will obtain Adaptate's antibody-based γδ T cell engager platform, including pre-clinical candidate and discovery pipeline programs.

Adaptate's γδ T cell engagers are designed to specifically modulate γδ T cell-mediated immune responses at tumor sites while sparing damage to healthy cells.

The planned acquisition of Adaptate follows Takeda's recently exercised option to acquire GammaDelta Therapeutics and is intended to further accelerate the development of innovative γδ T cell-based therapies.

Combining GammaDelta's cell therapy-based platform and Adaptate's antibody-based γδ T cell engager platform with Takeda's strong research and development organization positions Takeda to be at the leading edge in deploying the full potential of γδ T cells in the fight against cancer.

The planned acquisition complements Takeda's ongoing efforts to research and develop cell engagers for solid tumor applications, bolstered by the novel T cell engager COBRA platform, which was acquired from Maverick Therapeutics in another successful build-to-buy collaboration.

Adaptate was formed in 2019 as a spin-out company from GammaDelta with investment from Abingworth LLP and Takeda, in which Takeda received an exclusive right to purchase Adaptate for a pre-negotiated upfront payment.

The acquisitions of Adaptate and GammaDelta are expected to be finalized in Q1 of Takeda's fiscal year 2022, pending completion of review under applicable antitrust laws, including the Hart-Scott-Rodino Antitrust Improvements Act of 1976 in the US.

Takeda's oncology pipeline focuses on novel strategies that leverage the power of the immune system, with a focus on innate immunity.

Innate immune responses serve as the body's first defense mechanism against disease and involve the orchestration of a broad arsenal of mechanisms and cell types, including γδ T cells and natural killer cells, that may help to overcome cancer's ability to evade immune recognition.

Adaptate has discovered a unique set of antibodies that selectively modulate γδ T cell activity in the tumor microenvironment.

The antibodies provide a precisely targeted signal to the immune system, thereby offering the opportunity for superior efficacy and safety compared to conventional immuno-oncology approaches in solid tumors.

Its core R and D mission is to deliver novel medicines to patients with cancer worldwide through our commitment to science, breakthrough innovation and passion for improving the lives of patients.

Whether it's with our hematology therapies, our robust pipeline, or solid tumor medicines, we aim to stay both innovative and competitive to bring patients the treatments they need.

Takeda Pharmaceutical is a global, values-based, R and D-driven biopharmaceutical firm headquartered in Japan.
Login
Username:

Password:


Related Headlines